DAPT duration, de-escalation to clopidogrel and CYP2C19 genotyping
Balances bleeding risk (ARC-HBR, PRECISE-DAPT, bleeding on DAPT, oral anticoagulation) against thrombotic risk (complex PCI: left main, last patent vessel, two-stent bifurcation, CTO, ≥ 3 stents or lesions, 3 vessels, > 60 mm of stent; prior stent thrombosis, recurrent MI, diabetes, CKD, PAD, diffuse disease) to set the DAPT duration after ACS or elective PCI. Decides whether and when to de-escalate from ticagrelor or prasugrel to clopidogrel (not unguided in the first 30 days after ACS; genotype-guided earlier; not in CYP2C19 loss-of-function carriers), gives the switching doses, flags when CYP2C19 genotyping is worth doing (clopidogrel after left main or other high-risk PCI, early guided de-escalation, OAC after complex PCI, stent thrombosis on clopidogrel) and shows ESC 2023 ACS / 2024 CCS beside ACC/AHA 2025 ACS / 2023 chronic coronary disease recommendations.
- No high-risk features tickedFollow the default duration; reassess bleeding and ischaemic risk at every visit and at 12 months (DAPT score).
- No reason to de-escalateContinue the potent P2Y12 inhibitor for the planned course. De-escalation is an option for bleeding risk, bleeding, side effects (ticagrelor dyspnoea), the need for OAC, or cost.
- Not needed routinelyNeither ESC nor ACC/AHA recommends routine genotyping. It helps when clopidogrel is planned after high-risk PCI (left main, last vessel, 2-stent bifurcation, long or multiple stents), for early guided de-escalation after ACS, with OAC after complex PCI, after stent thrombosis on clopidogrel, and in East or South Asian patients.
- Default: DAPT 12 monthsIESC 2023 ACSAspirin plus prasugrel or ticagrelor (clopidogrel if they are unavailable, not tolerated or contraindicated).
- Event-free at 3–6 months, not high ischaemic risk: single antiplateletIIaESC 2023 ACSPreferably the P2Y12 inhibitor.
- High bleeding risk: monotherapy after 1 monthIIbESC 2023 ACSAspirin or P2Y12 inhibitor monotherapy after 1 month of DAPT.
- De-escalation (prasugrel / ticagrelor → clopidogrel) as an alternativeIIbESC 2023 ACS
- No de-escalation in the first 30 days after ACSIIIESC 2023 ACS
- OAC: triple therapy ≤ 1 week, then OAC + clopidogrel up to 12 monthsIESC 2023 ACSUp to 1 month of triple therapy when ischaemic risk is high.
- High ischaemic risk, no high bleeding risk: extended second antithromboticIIaESC 2023 ACSBeyond 12 months (ticagrelor 60 mg twice daily, prasugrel, clopidogrel, or rivaroxaban 2.5 mg twice daily).
- Default: DAPT at least 12 monthsIACC/AHA 2025 ACSTicagrelor or prasugrel preferred over clopidogrel after PCI for ACS.
- Tolerated DAPT ≥ 1 month: transition to ticagrelor monotherapyIACC/AHA 2025 ACSStop aspirin to reduce bleeding.
- High bleeding risk: single antiplatelet after 1 month of DAPTIIaACC/AHA 2025 ACS
- De-escalation to clopidogrel may be reasonable to reduce bleedingIIbACC/AHA 2025 ACS
- OAC: stop aspirin after 1–4 weeks, continue OAC + P2Y12 inhibitor (clopidogrel)IACC/AHA 2025 ACS
- Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720-3826.
- Vrints C, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45:3415-3537.
- Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the management of patients with acute coronary syndromes. Circulation 2025;151:e771-e862.
- Virani SS, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the management of patients with chronic coronary disease. Circulation 2023;148:e9-e119.
- Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther 2022;112:959-967.
- Angiolillo DJ, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017;136:1955-1975.
- Claassens DMF, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI (POPular Genetics). N Engl J Med 2019;381:1621-1631.
- Sibbing D, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing PCI (TROPICAL-ACS). Lancet 2017;390:1747-1757.
- Mehran R, et al. Ticagrelor with or without aspirin in high-risk patients after PCI (TWILIGHT). N Engl J Med 2019;381:2032-2042.